Association of CYP2D6 polymorphisms and extrapyramidal symptoms in schizophrenia patients receiving risperidone: a retrospective study.
Takahiro ItoKazuhiro YamamotoFuminori OhsawaIkuo OtsukaAkitoyo HishimotoIchiro SoraMidori HiraiIkuko YanoPublished in: Journal of pharmaceutical health care and sciences (2018)
Special attentions should be paid to the onset of extrapyramidal symptoms in schizophrenia patients identified as CYP2D6 IM undergoing risperidone therapy.